Baron H R, Stevenson B C, Phalen D N
School of Veterinary Science, Faculty of Science, University of Sydney, Sydney, New South Wales, Australia.
The Unusual Pet Vets, Melbourne, Victoria, Australia.
Aust Vet J. 2020 Jul;98(7):333-337. doi: 10.1111/avj.12936. Epub 2020 Mar 2.
To assess the efficacy of a commercially available in-water amphotericin B treatment for Macrorhabdus ornithogaster.
Clinical treatment trial.
Faecal shedding of 16 naturally infected budgerigars (Melopsittacus undulatus) was monitored while they were being treated using in-water amphotericin B, as per the manufacturer's instructions, for 10 days. Any birds that remained positive after 10 days received a further 10 day course of treatment. All birds were rechecked 16 days after the end of the second treatment period.
At the conclusion of treatment, 11 birds had stopped shedding M. ornithogaster, and 5 birds were still shedding. Sixteen days after the conclusion of the second treatment period, four birds that were negative after 10 days of treatment were shedding again, and two of the birds that were treated for 20 days were shedding. In addition, one bird from each treatment group died after treatment and before follow-up testing.
These findings represent a 36% treatment failure, suggesting that treatment with the commercially available, water-soluble amphotericin B has inconsistent efficacy against M. ornithogaster in some budgerigars in Australia and is not effective for eliminating it from budgerigar aviaries.
评估市售的水中两性霉素B治疗鸟巨嗜杆菌的疗效。
临床治疗试验。
按照制造商的说明，对16只自然感染的虎皮鹦鹉（虎皮鹦鹉）在使用水中两性霉素B治疗10天期间监测其粪便排菌情况。10天后仍呈阳性的任何鸟类接受另外10天的疗程治疗。在第二个治疗期结束后16天对所有鸟类进行复查。
治疗结束时，11只鸟已停止排出鸟巨嗜杆菌，5只鸟仍在排菌。第二个治疗期结束后16天，10天治疗后呈阴性的4只鸟再次排菌，接受20天治疗的2只鸟也在排菌。此外，每个治疗组各有1只鸟在治疗后和随访检测前死亡。
这些结果表明治疗失败率为36%，提示市售的水溶性两性霉素B对澳大利亚一些虎皮鹦鹉体内的鸟巨嗜杆菌治疗效果不一致，且无法从虎皮鹦鹉饲养场中消除该菌。
